Due to all of these features, GLUT1 targeting has been successfully used for the tumor-specific delivery of imaging probes for in vivo tumor diagnosis by positron emission tomography and drug delivery to tumors overexpressing this transporter [321,322]. The gene discussed is SLC2A1; the disease is neoplasm.